A federal jury in Trenton has found in favor of Merck & Co. Inc. in the first suit to go to trial over claims that its osteoporosis drug Fosamax causes fractured femurs.
After an hour and 20 minutes of deliberation on Monday, jurors voted 8 to 0 that the plaintiff failed to prove by a preponderance of the evidence that her fracture was of the so-called atypical type said to be caused by the drug.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
